Test ID NAT2O N-Acetyltransferase 2 Gene (NAT2), Full Gene Sequence, Saliva
Useful For
Identifying patients who may require isoniazid dosing adjustments
Genotyping patients who prefer not to have venipuncture done
Profile Information
Test ID | Reporting Name | Available Separately | Always Performed |
---|---|---|---|
NT2FO | NAT2, Full Gene Sequence | No | Yes |
NAT2S | NAT2, Gene Sequencing | No | Yes |
Special Instructions
Method Name
Polymerase Chain Reaction (PCR) Followed by DNA Sequence Analysis
(PCR is utilized pursuant to a license agreement with Roche Molecular Systems, Inc.)
Reporting Name
NAT2 Full Gene Sequence, SalivaSpecimen Type
SalivaMultiple saliva genotype tests can be performed on a single specimen after a single extraction. See Multiple Saliva Genotype Tests in Special Instructions for a list of tests that can be ordered together.
Container/Tube: Oragene DNA Self-Collection Kit (Supply T651: fees apply)
Specimen Volume: Full tube
Collection Instructions:
1. Fill tube to line.
2. Send specimen in original container per kit instructions.
Forms: New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (Supply T576) is available in Special Instructions.
Specimen Minimum Volume
1 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Saliva | Ambient |
Clinical Information
Arylamine N-acetyltransferase type 2 (NAT2) is a highly polymorphic phase 2 metabolic enzyme that conjugates hydrazine derivatives and aromatic amine drugs with acetyl-groups. NAT2 also is involved in the acetylation and activation of some procarcinogens.(1)
Individuals acetylate drugs at different rates by NAT2, and are described as having slow, intermediate, or fast acetylator phenotypes. A gradient exists in which the prevalence of slow acetylator phenotypes increases with decreasing distance to the equator. Near the equator, up to 80% of individuals may be slow acetylators, while in some more northern countries, as few as 10% of the population may have the slow acetylator phenotype.
A number of drugs are metabolized by NAT2 including procainamide, dapsone, nitrazepam, hydralazine, zonisamide, and isoniazid. Isoniazid is used to treat and prevent tuberculosis, and is still used as a primary treatment agent. Adverse reactions with isoniazid, which include nausea, drug-induced hepatitis, peripheral neuropathy, and sideroblastic anemia, are associated more often with a slow NAT2 acetylator phenotype. These individuals may require a lower dose to avoid adverse reactions.
The NAT2 gene contains a single intronless exon of 870 base pairs and encodes 290 amino acids. NAT2 is highly polymorphic and contains 16 known single nucleotide polymorphisms and 1 single base-pair deletion. These polymorphisms are combined into 36 known haplotype alleles. Each individual haplotype is predictive of either a fast or slow acetylator phenotype. Individuals with 2 fast haplotypes are predicted to be extensive (normal) metabolizers, while those with 1 fast and 1 slow haplotype are intermediate metabolizers, and those with 2 slow haplotypes are poor metabolizers.(2,3) Studies with patients who have different acetylator haplotypes have correlated the ratio of plasma N-acetylisoniazid/isoniazid drug concentrations with haplotypes, with slow and intermediate acetylators having lower ratios than fast acetylators.(4)
NAT2 Allele |
Nucleotide Change |
Amino Acid Change |
Predicted Acetylator Phenotype |
*4 |
None |
None |
Fast |
*5A |
341T->C |
I114T |
Slow |
*5B |
341T->C |
I114T |
Slow |
*5C |
341T->C |
I114T |
Slow |
*5D |
341T->C |
I114T |
Slow |
*5E |
341T->C |
I114T |
Slow |
*5F |
341T->C |
I114T K268R |
Slow |
*5G |
282C->T |
I114T
K268R |
Slow |
*5H |
341T->C 481C->T 803A->G 859Del |
I114T K268R
|
Slow |
*5I |
341T->C 411A->T 481C->T 803A->G |
I114T |
Slow |
*5J |
282C->T |
I114T R197Q |
Slow |
*6A |
282C->T |
R197Q |
Slow |
*6B |
590G->A |
R197Q |
Slow |
*6C |
282C->T |
R197Q |
Slow |
*6D |
111T->C |
R197Q |
Slow |
*6E |
481C->T |
R197Q |
Slow |
*7A |
857G->A |
G286E |
Slow |
*7B |
282C->T |
G286E |
Slow |
*10 |
499G->A |
E167K |
Undetermined |
*11A |
481C->T |
None |
Undetermined |
*11B |
481C->T 859Del |
S287 Frameshift |
Undetermined |
*12A |
803A->G |
K268R |
Fast |
*12B |
282C->T |
K268R |
Fast |
*12C |
481C->T |
K268R |
Fast |
*12D |
364G->A |
D122N |
Undetermined |
*13 |
282C->T |
None |
Fast |
*14A |
191G->A |
R64Q |
Slow |
*14B |
191G->A |
R64Q |
Slow |
*14C |
191G->A |
R64Q |
Slow |
*14D |
191G->A |
R64Q |
Slow |
*14E |
191G->A |
R64Q |
Slow |
*14F |
191G->A |
R64Q |
Slow |
*14G |
191G->A |
R64Q |
Slow |
*17 |
434A->C |
Q145P |
Undetermined |
*18 |
845A->C |
K282T |
Undetermined |
*19 |
190C->T |
R64W |
Undetermined |
Reference Values
An interpretive report will be provided.
Cautions
Saliva samples may contain donor DNA if obtained from patients who received heterologous blood transfusions or allogeneic blood or marrow transplantation. Results from samples obtained under these circumstances may not accurately reflect the recipient’s genotype. For individuals who have received blood transfusions, the genotype usually reverts to that of the recipient within 6 weeks. For individuals who have received allogeneic blood or marrow transplantation, a pretransplant DNA specimen is recommended for testing.
NAT2 genetic test results in patients who have undergone liver transplantation may not accurately reflect the patient's NAT2 status.
This test sequences the entire NAT2 gene. All variants, including novel variants not listed, should be detected. However, novel variants not described in the literature may be of unknown significance.
Mutations in the primer binding regions can affect the testing and, ultimately, the genotyping interpretation made.
Drug-drug interactions and drug or metabolite inhibition must be considered when dealing with heterozygous individuals. Drug or metabolite inhibition can reduce residual functional NAT2 catalytic activity. Acetaminophen is a significant inhibitor of NAT2.
Patients may develop isoniazid toxicity problems if liver and kidney function are impaired, even in the absence of slow or intermediate acetylator status.
Day(s) Performed
Varies
Report Available
7 days (not reported on Saturday or Sunday)Performing Laboratory

Test Classification
See Individual Test IDsCPT Code Information
81479-Unlisted molecular pathology procedure